Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77835 | 0.89 | ALDH1A1 (0.43) | OPRM1OPRL1ITGB3ITGA2B | |
| SCHEMBL76802 | 0.82 | ALDH1A1 (0.43) | OPRM1OPRL1 | |
| SCHEMBL76732 | 0.67 | L3MBTL1 (0.43) | OPRM1OPRL1 | |
| SCHEMBL4874626 | 0.66 | PARP10 (0.49) | OPRM1OPRD1OPRK1PARP10PARP15 | |
| SCHEMBL75015 | 0.64 | OPRM1 (0.51) | OPRM1OPRL1 | |
| SCHEMBL74850 | 0.64 | BCAT2 (0.40) | OPRM1OPRL1BCAT2OPRD1OPRK1 | |
| Terephthalamide SCHEMBL197479 | 0.63 | PARP1 (0.60) | PARP10PARP15F2 | |
| Terephthalamide SCHEMBL12613686 | 0.63 | PARP1 (0.60) | PARP10PARP15F2 | |
| Terephthalamide SCHEMBL472214 | 0.63 | PARP1 (0.60) | PARP10PARP15F2 | |
| SCHEMBL6426405 | 0.62 | CYP2C9 (0.40) | OPRM1BCAT2OPRD1OPRK1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | claimed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HSD11B1, HSD17B1, HSD17B11 | OPRM1 3899/4885OPRL1 4158/4885ITGB3 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.